ASBP
Price
$0.51
Change
-$0.03 (-5.56%)
Updated
Sep 5 closing price
Capitalization
N/A
CGEM
Price
$6.99
Change
+$0.08 (+1.16%)
Updated
Sep 5 closing price
Capitalization
412.93M
61 days until earnings call
Interact to see
Advertisement

ASBP vs CGEM

Header iconASBP vs CGEM Comparison
Open Charts ASBP vs CGEMBanner chart's image
Aspire Biopharma Holdings
Price$0.51
Change-$0.03 (-5.56%)
Volume$751.49K
CapitalizationN/A
Cullinan Therapeutics
Price$6.99
Change+$0.08 (+1.16%)
Volume$741.21K
Capitalization412.93M
ASBP vs CGEM Comparison Chart in %
Loading...
ASBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CGEM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASBP vs. CGEM commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASBP is a Buy and CGEM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (ASBP: $0.51 vs. CGEM: $6.99)
Brand notoriety: ASBP and CGEM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASBP: 5% vs. CGEM: 205%
Market capitalization -- ASBP: $0 vs. CGEM: $412.93M
ASBP [@Biotechnology] is valued at $0. CGEM’s [@Biotechnology] market capitalization is $412.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASBP’s FA Score shows that 1 FA rating(s) are green whileCGEM’s FA Score has 1 green FA rating(s).

  • ASBP’s FA Score: 1 green, 4 red.
  • CGEM’s FA Score: 1 green, 4 red.
According to our system of comparison, both ASBP and CGEM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASBP’s TA Score shows that 3 TA indicator(s) are bullish while CGEM’s TA Score has 4 bullish TA indicator(s).

  • ASBP’s TA Score: 3 bullish, 5 bearish.
  • CGEM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CGEM is a better buy in the short-term than ASBP.

Price Growth

ASBP (@Biotechnology) experienced а -11.02% price change this week, while CGEM (@Biotechnology) price change was -7.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

CGEM is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEM YTD gains are higher at: -42.611 vs. ASBP (-95.549).
ASBPCGEMASBP / CGEM
CapitalizationN/A413M-
EBITDAN/A-234.39M-
Gain YTD-95.549-42.611224%
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A265M-
Total DebtN/A1.52M-
TECHNICAL ANALYSIS
Technical Analysis
ASBPCGEM
RSI
ODDS (%)
Bearish Trend 2 days ago
21%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
26%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
22%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
36%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
38%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
42%
Bullish Trend 16 days ago
73%
Declines
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
24%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ASBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CGEM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFSSX16.180.06
+0.37%
Hartford Schroders Intl Cntrrn Val SDR
HQIRX21.84N/A
N/A
Hartford Equity Income R3
SSMHX347.13N/A
N/A
State Street Small/Mid Cap Equity Index
SILLX28.48-0.03
-0.11%
Franklin Global Equity C
TEGAX42.01-0.05
-0.12%
Touchstone Mid Cap Growth A

ASBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASBP has been loosely correlated with SPRO. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ASBP jumps, then SPRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASBP
1D Price
Change %
ASBP100%
-6.04%
SPRO - ASBP
62%
Loosely correlated
+0.47%
ALZN - ASBP
43%
Loosely correlated
+2.20%
ORIC - ASBP
29%
Poorly correlated
+1.02%
BRNS - ASBP
26%
Poorly correlated
-6.77%
CGEM - ASBP
23%
Poorly correlated
+1.16%
More

CGEM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEM has been loosely correlated with IDYA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEM jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEM
1D Price
Change %
CGEM100%
+1.16%
IDYA - CGEM
52%
Loosely correlated
+5.15%
BDTX - CGEM
48%
Loosely correlated
+2.44%
ATXS - CGEM
47%
Loosely correlated
+7.43%
TRDA - CGEM
47%
Loosely correlated
+1.34%
IMNM - CGEM
47%
Loosely correlated
+7.35%
More